{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["28(15)"],"submitter":["Peper-Gabriel JK"],"pubmed_abstract":["<h4>Purpose</h4>While patients responding to checkpoint blockade often achieve remarkable clinical responses, there is still significant unmet need due to resistant or refractory tumors. A combination of checkpoint blockade with further T-cell stimulation mediated by 4-1BB agonism may increase response rates and durability of response. A bispecific molecule that blocks the programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis and localizes 4-1BB costimulation to a PD-L1-positive (PD-L1+) tumor microenvironment (TME) or tumor draining lymph nodes could maximize antitumor immunity and increase the therapeutic window beyond what has been reported for anti-4-1BB mAbs.<h4>Experimental design</h4>We generated and characterized the PD-L1/4-1BB bispecific molecule PRS-344/S0"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pagination":["3387-3399"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9662934"],"repository":["biostudies-literature"],"pubmed_title":["The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner."],"pmcid":["PMC9662934"],"pubmed_authors":["Scholer-Dahirel A","Bossenmaier B","Peper-Gabriel JK","Gallou C","Bel Aiba RS","Hansbauer EM","Richter M","Grandclaudon M","Lelievre H","Rothe C","Morales-Kastresana A","Riviere M","Olwill SA","Jaquin TJ","Zettl M","Sancerne C","Blanc V","Pattarini L","Pavlidou M"],"additional_accession":[]},"is_claimable":false,"name":"The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.","description":"<h4>Purpose</h4>While patients responding to checkpoint blockade often achieve remarkable clinical responses, there is still significant unmet need due to resistant or refractory tumors. A combination of checkpoint blockade with further T-cell stimulation mediated by 4-1BB agonism may increase response rates and durability of response. A bispecific molecule that blocks the programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis and localizes 4-1BB costimulation to a PD-L1-positive (PD-L1+) tumor microenvironment (TME) or tumor draining lymph nodes could maximize antitumor immunity and increase the therapeutic window beyond what has been reported for anti-4-1BB mAbs.<h4>Experimental design</h4>We generated and characterized the PD-L1/4-1BB bispecific molecule PRS-344/S0","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-04T21:04:38.925Z","creation":"2025-04-04T21:04:38.925Z"},"accession":"S-EPMC9662934","cross_references":{"pubmed":["35121624"],"doi":["10.1158/1078-0432.CCR-21-2762"]}}